Skip to main content

Remote Job Finders (RJF)

First quarter earnings continue to arrive, with analysts demanding more from cautious Pfizer and Eli Lilly expecting more revenue; the FDA taps Katherine Szarama as Vinay Prasad’s controversial FDA tenure ends; oncology veterans miss Richard Pazdur at the agency’s first adcomm in nine months; and QurAlis and Corcept Therapeutics spark renewed hope in ALS.
Pfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening
Scroll to top